Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: -
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

Pharmos Corp

PHA1:GR

Ticker Delisted

Company Profile for Pharmos Corp (PHA1)

Pharmos Corporation is a bio-pharmaceutical company that discovers and develops new drugs to treat a range of neuroinflammatory disorders. The company has a portfolio of drug candidates under development. Pharmos's main product, dexanabinol, is a synthetic non-psychotropic cannabinoid currently in late stage clinical development for the treatment of traumatic brain injury (TBI).

Contact Information

Pharmos Corp

99 Wood Avenue South
Suite 302
Iselin, NJ 08830
United States
Phone: 1-732-452-9556
Fax: 1-732-452-9557

Key Executives for Pharmos Corp (PHA1)

Robert F JohnstonChairmanEric W FangmannActing President/Acting CFO

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil